REFERENCES
- Tonato M., Mosconi AM, Martin C. Safety profile of gemcitabine. Anticancer Drugs 1995; 6 (suppl 6): 27-32.
- Burstein HJ Radiation recall dermatitis from gemc-itabine. J Clin Oncol 2000; 18 (3): 693-694.
- Castellano D, Hitt R, Cortes-Funes H, Romero A, Rodriguez-Peralto JL. Radiation recall reaction induced by gemcitabine. J Clin Oncol 2000; 18 (3): 695–696.
- Bar-Sela G, Beny A, Bergman R, Kuten A. Gemcitabine-induced radiation recall dermatitis: case report. Tumori 2001; 87 (6): 428–430.
- Jeter MD, Jane PA, Brooks S, Burstein HJ, Wen P, Fuchs CS, et al. Int J Radiat Oncol Biol Phys 2002; 53 (2): 394-400.
- Brandes A, Reichmann U, Plasswilm L, Bamverg M. Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine—a report of three cases. Anticancer Drugs 2000; 11 (1): 15–17.
- del Pozo J, Martinez W, Yebra-Pimentel MT, Almagro M, Pena-Penabad C, Fonseca E. Linear immunogolobulin A bullous dermatosis induced by gemcitabine. Ann Pharmacother 2001; 35 (7): 891–893.
- Kuku I, Kaya E, Sevinc A, Aydogdu I. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesotelioma. J Eur Acad Dermatol Venerol 2002; 16 (3): 271–272.
- Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome / toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1 (16): 349–360.
- Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18 (3): 485–495.
- Schulz JT, Sheridan RL, Ryan CM, MacKool B, Tompkins RG. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21 (3): 199–204.